Florencia McAllister's guest appearances

Florencia McAllister

Finding Genius Podcast

FutureTech Podcast

Laura Potterat

Marc Guell

Paul Turner

Jan Vijg

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

Kim Kush

OwlTail

With an average survival rate of less than 10 percent within five years of diagnosis, pancreatic cancer remains one of the most deadly and aggressive. But in the Department of Clinical Cancer Prevention at the University of Texas, Dr. Florencia McAllister’s research may lead to insights which could forever change this grim prognosis and pave the way for an effective pancreatic cancer treatment. Her work centers around developing a better understanding of how the microbiome of pancreatic tumors interacts with the rest of the body—and the immune system in particular. What is it that allows a pancreatic tumor to remain unseen by the immune system, and what might the bacteria in pancreatic tumors have to do with it? Does the presence of certain species of bacteria in pancreatic tumors indicate a better prognosis than others? In this episode, Dr. McAllister explains the details of how this research is being done, what they’ve discovered, where the future of her work is headed, and so much more. Tune in to discover:  How tumor microbiomes differ between long and short-term survivors of pancreatic cancer How the microbiome of pancreatic tumors differs from the microbiome of the rest of the pancreas What conditions create a high risk of pancreatic cancer development 

<p>With an average survival rate of less than 10 percent within five years of diagnosis, <a href="https://www.futuretechhealth.com/podcasts/safely-stripping-away-a-cancer-cells-defenses-robin-bannister-ph-d-care-oncology-clinic/" rel="nofollow" target="_blank">pancreatic cancer</a> remains one of the most deadly and aggressive. But in the Department of Clinical Cancer Prevention at the University of Texas, Dr. Florencia McAllister’s research may lead to insights which could forever change this grim prognosis and pave the way for an effective pancreatic cancer treatment. Her work centers around developing a better understanding of how the microbiome of pancreatic tumors interacts with the rest of the body—and the immune system in particular. What is it that allows a pancreatic tumor to remain unseen by the immune system, and what might the bacteria in pancreatic tumors have to do with it? Does the presence of certain species of bacteria in pancreatic tumors indicate a better prognosis than others? In this episode, Dr. McAllister explains the details of how this research is being done, what they’ve discovered, where the future of her work is headed, and so much more. Tune in to discover:</p> <ul> <li>How tumor microbiomes differ between long and short-term survivors of pancreatic cancer</li> <li>How the microbiome of pancreatic tumors differs from the microbiome of the rest of the pancreas</li> <li>What conditions create a high risk of pancreatic cancer development</li> </ul>

The Pancreatic Cancer Microbiome—Florencia McAllister, MD—Department of Clinical Cancer Prevention, MD Anderson Center at the University of Texas

Pancreatic cancer is one of the most aggressively malignant cancers that exist; despite all the knowledge we have about the mechanisms at play in pancreatic cancer and many attempts at finding a treatment that works, the survival rate is only nine percent in five years after diagnosis. In the Department of Clinical Cancer Prevention at the University of Texas, Dr. Florencia McAllister’s goal is to change this by developing better preventative and therapeutic strategies for pancreatic cancer. She is focused on understanding the interaction between the immune system and very early-stage cancer. How is it that cancer can emerge in the body yet remain undetected by the immune system? And if we can answer this question, can we also figure out how to change it? Part of this research involves a look at the microbiome of pancreatic tumors and a comparison to the microbiome of the gut. What, if any, are the associations between the gut and tumor microbiomes, and between the bacteria in tumors and the immune response? Answering these questions is the crux of Dr. McAllister’s work, and she joins the podcast today to discuss all the details. By tuning in, you will learn:  What Dr. McAllister and her team has learned by comparing the tumor microbiomes of long-term versus short-term survivors of pancreatic cancer How the microbiome of pancreatic tumors differs from the microbiome of the rest of the pancreas What causes someone to be at high risk for developing pancreatic cancer 

<p>Pancreatic cancer is one of the most aggressively malignant cancers that exist; despite all the knowledge we have about the mechanisms at play in <a href="https://www.futuretechpodcast.com/podcasts/combatting-cancer-charles-j-meakin-md-mha-medical-director-care-oncology-clinic-usa-finding-new-ways-to-fight-cancer-combinations-of-drugs-and-rethinking-treatment/" rel="noopener nofollow" target="_blank">pancreatic cancer</a> and many attempts at finding a treatment that works, the survival rate is only nine percent in five years after diagnosis. In the Department of Clinical Cancer Prevention at the University of Texas, Dr. Florencia McAllister’s goal is to change this by developing better preventative and therapeutic strategies for pancreatic cancer. She is focused on understanding the interaction between the immune system and very early-stage cancer. How is it that cancer can emerge in the body yet remain undetected by the immune system? And if we can answer this question, can we also figure out how to change it? Part of this research involves a look at the microbiome of pancreatic tumors and a comparison to the microbiome of the gut. What, if any, are the associations between the gut and tumor microbiomes, and between the bacteria in tumors and the immune response? Answering these questions is the crux of Dr. McAllister’s work, and she joins the podcast today to discuss all the details. By tuning in, you will learn:</p> <ul> <li>What Dr. McAllister and her team has learned by comparing the tumor microbiomes of long-term versus short-term survivors of pancreatic cancer</li> <li>How the microbiome of pancreatic tumors differs from the microbiome of the rest of the pancreas</li> <li>What causes someone to be at high risk for developing pancreatic cancer</li> </ul>

An Analysis of Pancreatic Tumor Microbiomes—Florencia McAllister, MD—Department of Clinical Cancer Prevention, MD Anderson Center at the University of Texas